Related Experiment Videos
Haemophilus B polysaccharide vaccine. Antibody kinetics in 17- to 71-month-old children
K P Ramsey1, L A Popejoy, S W Jesse
1Department of Pediatrics, William Beaumont Army Medical Center, El Paso, Tex. 79920-5001.
Insights
Antibody levels from Haemophilus B polysaccharide vaccines decline significantly over six months, especially in younger children. This suggests antibody kinetics, not just initial response, is crucial for vaccine use.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Polysaccharide vaccine antibody response varies with age, with younger individuals showing lower and less reliable antibody levels.
- The long-term persistence of antibodies induced by polysaccharide vaccines is not well understood.
Purpose of the Study:
- To investigate the antibody kinetics of the beta-Capsa 1 Haemophilus B polysaccharide vaccine in children.
- To assess the durability of the immune response over a six-month period post-vaccination.
Main Methods:
- Studied antibody kinetics of beta-Capsa 1 vaccine in 185 children aged 17–71 months.
- Measured serum antibody levels at three weeks and six months post-vaccination.
Main Results:
- 90% of children vaccinated at ≥2 years achieved protective antibody levels at three weeks; 45% vaccinated at 18 months achieved these levels.
- Antibody levels significantly decreased in all children within six months.
- For children vaccinated at 18 months, antibody levels at six months were similar to pre-vaccination levels.
Conclusions:
- Antibody kinetics following polysaccharide vaccination are critical for determining vaccine efficacy.
- The findings suggest that the timing of vaccination influences long-term antibody persistence.
- Consideration of antibody decay is essential for the clinical application of polysaccharide vaccines.
Abstract:
The antibody response to polysaccharide vaccines is well known to be age variable, with younger infants or children responding less dependably and with lower antibody levels. The fate of these induced antibodies over time is less well understood. We studied the antibody kinetics of beta-Capsa 1, a Haemophilus B polysaccharide vaccine, in 185 children aged 17 to 71 months. Ninety percent of the children vaccinated at age 2 years or older achieved reportedly immune serum antibody levels three weeks after vaccination; 45% vaccinated at age 18 months achieved such levels. In six months, the antibody levels fell significantly in all children. In those vaccinated at age 18 months, the levels six months after vaccination were not significantly different from those prior to vaccination. Our study raises the possibility that antibody kinetics may be as critical a consideration as immediate antibody response in deciding the proper clinical use of a polysaccharide-based vaccine.